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Abstract
Background: Setting priorities is important in health research given the limited resources available for research.
Various guidelines exist to assist in the priority setting process; however, priority setting still faces significant
challenges such as the clear ranking of identified priorities. The World Health Organization (WHO) proposed a
Disability Adjusted Life Year (DALY)-based model to rank priorities by research area (basic, health systems and
biomedical) by dividing the DALYs into ‘unavertable with existing interventions’, ‘avertable with improved efficiency’
and ‘avertable with existing but non-cost-effective interventions’, respectively. However, the model has conceptual
flaws and no clear methodology for its construction. Therefore, the aim of this paper was to amend the model to
address these flaws, and develop a clear methodology by using tuberculosis in South Africa as a worked example.
Methods: An amended model was constructed to represent total DALYs as the product of DALYs per person and
absolute burden of disease. These figures were calculated for all countries from WHO datasets. The lowest figures
achieved by any country were assumed to represent ‘unavertable with existing interventions’ if extrapolated to
South Africa. The ratio of ‘cost per patient treated’ (adjusted for purchasing power and outcome weighted)
between South Africa and the best country was used to calculate the ‘avertable with improved efficiency section’.
Finally, ‘avertable with existing but non-cost-effective interventions’ was calculated using Disease Control Priorities
Project efficacy data, and the ratio between the best intervention and South Africa’s current intervention,
irrespective of cost.
Results: The amended model shows that South Africa has a tuberculosis burden of 1,009,837.3 DALYs; 0.009% of
DALYs are unavertable with existing interventions and 96.3% of DALYs could be averted with improvements in
efficiency. Of the remaining DALYs, a further 56.9% could be averted with existing but non-cost-effective
interventions.
Conclusions: The amended model was successfully constructed using limited data sources. The generalizability of
the data used is the main limitation of the model. More complex formulas are required to deal with such potential
confounding variables; however, the results act as starting point for development of a more robust model.
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Background
The demand for health research far outstrips the current
financial and capacity resources made available to do so
[1], and hence it is important to set priorities when mak-
ing decisions about what research to undertake. Further-
more, priorities should be set in a transparent, rational
and systematic manner. This need was articulated by the
Commission on Health Research for Development in
1990 [2], and led to the formation of the Council on
Health Research for Development (COHRED), which
celebrates its 20th anniversary this year. COHRED is ar-
guably the world leader in priority setting in health re-
search, and over the past two decades has fostered an
international movement towards procedural priority set-
ting. While COHRED does not endorse a specific prior-
ity setting process, they do provide general guidelines on
best practices for countries that wish to set health re-
search priorities [3]. Broadly, processes should involve
quantitative data inputs as well as participation from
stakeholders, such as researchers, funders, politicians,
community members, health workers, economists and
civil servants. These two inputs are then used to identify
priorities, which can range from specific research ques-
tions to broader disease areas. The identified priorities
are subsequently ranked in order of importance, usually
with a greater focus on stakeholder input and less focus
on quantitative data inputs. There are a variety of frame-
works, like the Combined Approach Matrix [4] or the
Essential National Health Research [5] framework, which
provide guidelines on priority identification and ranking,
such as what data is relevant, which stakeholders should
be involved in the identification of research priorities,
what criteria are used in priority identification, and how
the research priorities identified are ranked. However,
despite the COHRED guidelines and a plethora of
frameworks, priority setting still faces significant chal-
lenges, such as the uncertainty of health research out-
comes, ensuring that the priority setting process is
transparent and fair, and defining relevant criteria to
identify and rank priorities [6]. This paper will address
the challenge of subjectivity in ranking criteria, and the
need for a clearly defined, transparent and quantitative
methodology to rank priorities [7]. Importantly, this
methodology must also be relatively simple, as priority
setting can be most beneficial in resource-scarce devel-
oping countries, which generally have a paucity of data
and expertise relevant for ranking priorities [7]. The
model presented in this paper does not intend to replace
the holistic and inclusive approach advocated by
COHRED, but rather is presented as a resource to sup-
plement the priority setting process.
Current ranking techniques are divided into two cat-
egories, either direct or indirect [3]. Direct techniques
involve contrasting two priorities and selecting the one
of greater importance such as a discrete choice method.
Indirect techniques utilise a scoring system that scores a
priority based on a list of criteria and then calculates a
cumulative score using a formula that incorporates all
the criteria listed. While this latter method increases the
transparency and standardises ranking of priorities, the
criteria used, and their weighting, is determined by
stakeholder input and is therefore highly subjective. The
World Health Organization (WHO) proposed an alter-
native, quantitative-based, model for ranking priorities
by research area in 1996, as outlined in Fig. 1.
In this model, Disability Adjusted Life Years (DALYs)
are used to construct a quadrangle for a particular dis-
ease. This quadrangle consists of two axes, namely how
much of the population affected could be treated with
interventions, and how effective the interventions could
be at treating the disease. Four subdivisions are then
listed. Firstly, how well the current interventions are
working, both in terms of treatment efficacy and popula-
tion coverage, defined as the ‘averted with current mix
of interventions and population coverage’ section. Sec-
ondly, what additional coverage could be obtained with
gains in health systems and policy research, defined as
the ‘avertable with improved efficiency’ section. Thirdly,
what gains in coverage could be obtained with biomed-
ical research to reduce the cost of interventions, defined
as the ‘avertable with existing but non-cost-effective in-
terventions’ section. Finally, gains in effectiveness of in-
terventions from basic and clinical research to identify
new interventions, defined as the ‘unavertable with exist-
ing interventions’ section. By using this model, priority
areas can be identified and ranked in terms of disease
and research area automatically, as the area of a section
would indicate the degree to which research in that dis-
ease field (e.g. HIV health systems and policy research)
should be a priority relative to other disease fields. How-
ever, in its current state, the WHO model has some
major flaws, both in the methodology and inherent to its
structure.
Firstly, one of the main assumptions of the WHO
model is that the sum of all the components contribut-
ing to coverage and efficacy of interventions would
neatly sum to 100% coverage and 100% efficacy. By way
of example, in Fig. 1, current interventions (x value on
x-axis) cover approximately 30% of the population, with
an additional 40% coverage possible with improvements
in efficiency, and 30% additional coverage achievable
with use of existing but non-cost-effective interventions.
However, it is possible to envisage a situation where just
improving efficiency could increase coverage by an extra
60%, or just using non-cost-effective interventions could
increase coverage by an extra 60%. The total coverage in
such a case would thus be the baseline of 30% plus 120%
if both efficiency improvements were made and non-
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cost-effective interventions adopted, to a total of 150%
coverage. As it is not possible to achieve such a thing, it
is important to adapt the model to show a relativistic
improvement, as the problem arises due to the assump-
tion of mutual exclusivity in the model. The model as-
sumes that, with the current burden of disease, you
could increase coverage by either increasing efficiency or
using non-cost-effective interventions. However, these
gains are both based on the current disease burden, yet
if improvements in efficiency were to be made, then the
disease burden would change and the contribution that
non-cost-effective measures could make would only
apply to the new disease burden. Thus, it makes more
sense to look at relativistic changes, such as the subse-
quent impact of the adoption of non-cost-effective inter-
ventions if improvements to efficiency were made, or
vice versa.
Secondly, the current construction of the WHO model
assumes that use of non-cost-effective interventions and
increases in health system efficiency will only increase
population coverage, and not the efficacy of the inter-
ventions. However, there is no reason to assume that
this will always be the case, and therefore the model
would also need to be amended to allow for changes in
both population coverage and efficacy from gains in
health systems efficiency and use of non-cost-effective
interventions. Finally, the current axes are presented in
terms of percentage coverage and percentage efficacy of
interventions against a disease. However, because disease
burdens vary, it limits the viability of cross-comparisons
between diseases. Furthermore, it is unclear what
‘coverage in the population’ means, as it could apply to
both provision of treatment for those with the disease as
well as preventive measures for the ‘at risk’ population.
Because of these limitations, the axes of the model
should also be adapted to present the results in terms of
absolute disease burden figures, and not percentage
coverage or efficacy. Furthermore, the y-axis of ‘coverage
in the population’ must be more clearly defined and able
to incorporate both curative and preventive measures.
It is perhaps for these reasons that the WHO model
has largely remained unused, although it has been refer-
enced as a model that could be incorporated into
current priority setting frameworks, such as the Essential
National Health Research [5] or Combined Approach
Matrix frameworks [4]. This is compounded by the fact
that, even if the model were made theoretically sound,
practically, it is not an easy model to construct since
data on treatment coverage and efficacy are not widely
available and no formal methodology has ever been pro-
posed for the construction of the quadrangle. Therefore,
the present paper focuses on developing an amended
model based on the principles of the WHO model and
attempts to define an explicit methodology for its con-
struction using quantitative data. The viability of the
amended model was then explored using tuberculosis
(TB) in South Africa as a worked example.
Methods
Amendment of the WHO model
The axes of the amended model were changed to those
of disease severity (as measured by DALYs per person)
Fig. 1 WHO model for ranking of research priorities [8]. Ability to tackle the burden of disease is represented by the efficacy of interventions, and
the coverage in the population. Improvements in coverage can be gained via either health systems research or biomedical research to reduce
the cost of interventions. Efficacy gains can arise from research to identify new interventions
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and disease burden (as measured by both prevalence
and incidence). The revised model thus seeks to reduce
severity and disease burden, and subsequently the size of
the quadrangle, as opposed to increasing coverage and
efficacy as in the original WHO model. Similar to the
WHO model, the amended model acknowledges that
there is a particular severity and burden of the disease
that is unavertable with existing interventions, as well as
a larger severity and burden that the current interven-
tion mix is averting. In addition, the portion of the dis-
ease that is avertable, could be averted either via
increases in efficiency of the health system or use of
existing but non-cost-effective interventions, as stipu-
lated by the WHO model. In the amended model, these
two routes are allowed to have impact on both burden
and severity measures of the disease (Fig. 2).
The amended model also nests the ‘avertable with
existing but non-cost-effective interventions’ section
within the ‘avertable with improved efficiency’ section
(and vice versa, if so desired), to address the issues of
relativistic changes and mutual exclusivity in the original
WHO model.
Finally, the revised model appends the additional dis-
ease burden and DALYs that are ‘averted with current
mix of interventions and population coverage’ to the
outer limits of each axis.
Application of amended model to TB
The construction of the amended model for TB involved
three stages, as outlined in Fig. 3. To construct the x-
axis, both incidence and prevalence estimates were con-
sulted. The Global Tuberculosis Control report [9]
provides prevalence measures as point estimates of the
number of individuals with a disease in the population
at a given time based on survey data. It also provides in-
cidence measures as estimates of new and recurring
cases of TB over a 1 year period based on modelling.
Disease burden was calculated as the sum of the inci-
dence and prevalence per 100,000 estimates for South
Africa. While the simple addition of prevalence and inci-
dence estimates may result in overestimation of the dis-
ease burden (as some of the incident cases will be
measured twice by the point prevalence), it does allow
for a more accurate reflection of diseases with high inci-
dence but low prevalence (e.g. diarrheal diseases), as well
as chronic diseases that may have a low incidence, but a
much higher prevalence (e.g. hypertension). It also al-
lows for both preventive measures, which largely impact
disease incidence, and curative measures, which impact
disease prevalence, to be accounted for. Therefore, it
was important to include both measures of incidence
and prevalence in the calculation of disease burden. The
disease burden was then applied to South Africa’s popu-
lation size in 2004 to get an absolute disease burden
score using equation 1:
prevalence þ incidenceper 100; 000ð Þ x
South Africanpopulation=100; 000ð Þ
¼ absolutediseaseburden
ð1Þ
For the y-axis, South Africa’s DALYs per person (pp)
were calculated using equation 2, with age standardised
DALY rates sourced from WHO 2004 disease burden
data [8] and TB prevalence and incidence rates from
2004 in the 2006 Global Tuberculosis Control report [9].
DALYsper 100; 000= prevalenceþ incidenceper 100; 000ð Þ
¼ DALYsper person
ð2Þ
This quadrangle therefore represents the entire DALYs
of TB for South Africa, which can be attributed to the
three mechanisms outlined in the amended model,
namely the proportion which is unavertable with existing
interventions, the proportion which is avertable with im-
proved efficiency, and the proportion which is avertable
with existing but non-cost-effective interventions.
The second stage was to determine that component of
the quadrangle which was currently unavertable with
existing interventions, and to append the additional
DALYs that are currently being averted. To determine
this, DALYs pp and disease burden were calculated for
each country where both data was available (Additional
file 1). Those countries which had no DALYs, incidence,
or prevalence per 100,000 were excluded. Of the
remaining countries, the lowest DALY pp score was
appended to the y-axis. For the x-axis, the lowest disease
Fig. 2 Amended model based on the original WHO model. DALYs
are represented as a product of disease burden (incorporating both
incidence and prevalence measures) and DALYs due to the disease
per person. DALYs which are currently being averted are appended
to the ends of the axes, while those that currently exist could be
averted with either health systems research to improve efficiency,
biomedical research to reduce the cost of existing interventions, or
research on new interventions to tackle the portion of the burden
that not even the best existing interventions can avert
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burden score was extrapolated using equation 3 to get a
hypothetical absolute lowest disease burden for the
South African population.
The resultant quadrangle was assumed to estimate
that portion of the DALYs unavertable with existing in-
terventions, as these are the best figures that any coun-
try has been able to achieve. However, even in the best
performing countries used to construct this estimate
there are other determinants of health, such as climate.
These factors may prevent optimal treatment of a dis-
ease (e.g. monsoons) or assist in treatment efficacy (e.g.
warm climates). Thus, there is a degree of uncertainty
around the estimate.
countrywithcombined lowest incidenceþ prevalenceper 100; 000ð Þ x
South Africanpopulation=100; 000ð Þ
ð3Þ
To determine the degree of disease burden currently be-
ing averted, the worst performing countries, both in terms
of DALYs pp and disease burden, were identified. The
same methodology used to calculate the hypothetical best
Fig. 3 Construction of amended model. Stage 1: Construction of the two axes to create the total DALYs attributable to a particular disease. Stage
2: Determination of the DALYs currently being averted as well as those unavertable with existing interventions, based on the best and worst
performing member states. Stage 3: Division of current DALYs into those that could be reduced with improvements in health systems, and those
that could be reduced with reduction in costs of existing interventions
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disease burden for South Africa was used to calculate the
hypothetical worst disease burden for South Africa. These
figures were then appended to the current DALY pp and
disease burden estimates. The premise being that South
Africa is averting at least as much as the difference be-
tween itself and the worst performing countries, if not
more so, as even the worst performing countries are likely
to be combating TB in some manner.
Two approaches were taken to subdivide the
remaining disease burden (Stage 3 of Fig. 3). In the first
approach, the component which could be averted with
improved efficiency was first calculated, and then the
remaining disease burden was used to calculate what
could be averted with existing but non-cost-effective in-
terventions. In the second approach, the component
which could be averted with existing but non-cost-
effective interventions was first calculated, and then the
remaining disease burden was used to calculate what
could be averted with improvements in efficiency. For
both cases, calculations were performed in the same
manner. To determine the proportion avertable with im-
proved efficiency, cost per patient treated (CPP) data
from 2008 and 2009 (both in US dollars, and adjusted
for purchasing power parity) was used. Data from 2008/
2009 was used as this data has only recently been re-
corded by WHO and hence there was no data available
for 2004. This value was weighted by DALY pp data to
control for the potential differences in outcomes of the
treatment, as such:
cost per patient treated= 1=DALY pp½ 
¼ weighted cost per patient ð4Þ
In equation 4, countries with poor treatment outcomes
(i.e. high DALY pp values) will have a small denomin-
ator, and hence their cost per patient will be inflated. Al-
ternatively, countries that spend slightly more, but
achieve better outcomes, will have a larger denominator
and hence their cost per patient will be deflated. The ra-
tio between South Africa’s weighted CPP and the lowest
weighted CPP obtained was hypothesized to represent
the proportion of total disease burden reduction which
could be obtained with improvements in efficiency. It
was assumed that the reduction would be an equivalent
reduction in DALYs pp and disease burden, and hence
the ratio between the axes remained fixed. The degree of
the disease which is avertable using existing but non-
cost-effective interventions was calculated using TB
cost-effectiveness data from the Disease Control Prior-
ities Project report [10]. This report models efficacies of
current treatments for TB in six global regions, as well
as hypothetical best efficacies of interventions in those
regions and their respective costs. The ratio between the
highest average efficacy achievable by all the existing
interventions mentioned in the sub-Saharan Africa
region (irrespective of cost) and the efficacy of South
Africa’s current intervention program was assumed to
represent the proportion of the disease burden which
could be averted with existing but non-cost-effective
interventions. Similarly, it was assumed that this
would be equally reflected in disease burden and




Table 1 summarises all the data used in construction of
the amended model. South Africa had a DALY pp value
of 1.48. The country with the lowest value was Kiribati,
with a value of 0.12, whereas the country with the high-
est value was the United Arab Emirates, with a value of
13.47 DALYs pp. This is a surprising result for the
United Arab Emirates, as dry climates are known to
speed TB recovery [11]. Potential explanations for this
include the relatively high contribution by emigrants
from South and Southeast Asian countries [12], the in-
crease in multiple drug resistant TB, as well as a novel
strain of TB among the indigenous population [13]. In
terms of disease burden, the United Arab Emirates has a
combined prevalence and incidence per 100,000 of 5.7,
ranking seventh lowest amongst the member states
(Additional file 1).
This suggests that relatively few people contract TB,
but that it is a particularly severe strain. While this does
call into question the validity of using the United Arab
Emirates as a baseline for worst case scenario, the Cook
Islands, Burkina Faso, Mali and Togo all have DALYs pp
of greater than 9 (Additional file 1), and have vastly dis-
parate climates, genetics and disease profiles. Hence, a
DALY pp value of 13.47 is within acceptable range, but a
value between 9 and 13 could be a more conservative es-
timate. The lowest DALY pp country, Kiribati, has one
of the highest incidence rates of TB in the Western
Pacific region [14]; however, it also has stringent treat-
ment guidelines, with patients being quarantined for
2 months during treatment, and then further confined
to a specialised centre until fully healed [15]. This com-
bination of high incidence and strict treatment could ac-
count for the resultant low DALY pp value. The small
population may limit the generalizability of such a treat-
ment, and this is supported by similar small countries
also achieving low DALY pp rates (Additional file 1);
however, it should be noted that larger countries, like
Australia and Switzerland, have DALY pp values of 0.15
and 0.17, respectively. Therefore, both United Arab
Emirates and Kiribati figures were used in the construc-
tion of the amended model as they did not deviate from
the general trend of the member states (Fig. 4).
Hacking and Cleary Health Research Policy and Systems  (2016) 14:10 Page 6 of 11
In terms of disease burden, South Africa had a com-
bined absolute incidence and prevalence of 682,322.5.
Monaco had the lowest combined prevalence and inci-
dence of 1.78 per 100,000, whereas Namibia had the
highest with 3,342 per 100,000. This extrapolated to a
hypothetical best and worst disease burden for South
Africa of 721.65 and 1,352,915, respectively. Again, the
high levels of TB in Namibia, which is a desert area, are
unexpected. Possible explanations for this include the
high co-morbidity with HIV [16] as well as a high rate of
drug resistant TB [17]. Interestingly, similar to the
United Arab Emirates, Namibia appears to be plagued
by a specific subset of TB which could be exacerbating
its disease burden [18]. These differences in disease pro-
files do limit the generalizability of using Namibia as a
worst case scenario, particularly as Namibia is unique in
having both the highest incidence per 100,000 and the
highest prevalence per 100,000 (by way of example,
Cambodia has the second highest prevalence but only
the 11th highest incidence). Namibia’s disease burden
score is also disproportionately high compared to the
other top five countries (Cambodia, Swaziland,
Central African Republic and South Africa) which
range from 1,683 to 1,844 (Fig. 4). On the other end
of the scale, Monaco had the lowest disease burden
score; however, this was relatively similar to other low
scoring countries. Therefore, Monaco was used in the
construction of the amended model, and both
Namibia and Cambodia were used due to the poten-
tial of Namibia as an outlier. From this data, the
amended model was constructed as shown in Fig. 5
(Namibia is included as a shaded extra).
The total potential DALYs that TB could inflict in
South Africa are between 10,070,106.53 and
18,250,705.05 depending on whether Namibia was con-
sidered; however, up to 94.5% of this was averted in
2004 due to the current intervention mix. Importantly,
this includes not only direct healthcare such as curative
and preventive medicine, but also includes broader inter-
ventions such as sanitation and access to health, as well
as confounders such as strain subtype and genetic sus-
ceptibility to the disease. As a result of these factors,
South Africa’s actual burden of TB was 1,009,837.3
DALYs. Of this, 86.6 DALYs (0.009%) were unavertable
with existing interventions (too small to be seen at the
scale of Fig. 5).
Subdividing existing DALYs
The weighted CPP for South Africa was US$ 404.45,
with the lowest weighted CPP being achieved by
Yemen, at a cost of US$ 14.29. The Disease Control
Priorities Project (DCPP) reports a lowest theoretical
cost per patient based on their model of US$ 12 [10],
thus, the DALY weighted figure in Yemen is within
range of their estimates. When adjusted for purchas-
ing power parity, South Africa had a value of Inter-
national (Int.)$ 621.33, and Namibia replaced Yemen
as the most effective with a DALY weighted value of
Int.$ 22.81 (compared to Yemen with a value of Int.$
24.29). Namibia has managed to continuously improve
its health delivery in response to TB since 2004, the
year in which it had its highest case notification rate
of 16,156. In 2008, this had been reduced to 13,737,
with an estimated 83% treatment success rate [19]. By
using 2004 burden of disease data with 2008 finan-
cing data, it is likely that the figure for Namibia is an
underestimation of its true cost-per-patient. Unfortu-
nately, no chronologically matched data exists, which
is a limitation of this model, and so it is the best esti-
mate available. Furthermore, Namibia’s Int.$ was simi-
lar to other countries with the lowest purchasing
power adjusted DALY weighted cost (Fig. 4), which
strengthens the validity of the figure. Hence, it was
Table 1 List of figures used to construct amended model
Data type Value Country
DALY data
DALYs per person (PP) 1.48 South Africa
Best DALYs PP 0.12 Kiribati
Worst DALYs PP 13.47 United Arab
Emirates
Disease burden (DB) data
DB/100,000 1,683 South Africa
DB 682,322.47 South Africa
Best DB/100,000 1.78 Monaco
Best DB 721.65 South Africa
Worst DB/100,000 3,342 Namibia
Worst DB 1,354,915 South Africa
Cost per patient (CPP)
Weighted CPP 404.45 South Africa
Best weighted CPP 14.29 Yemen
Fold reduction 28.30
Weighted CPP PP adjusted 621.33 South Africa
Best weighted CPP PP adjusted 22.81 Namibia
Fold reduction PP adjusted 27.24
Cost efficiency (DCPP) data
Sub-Saharan Africa baseline treatment
active infection
33%
Sub-Saharan Africa best treatment
active infection
71%




DCPP, Disease Control Priorities Project
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Fig. 4 DALYs per person, Disease Burden and DALY weighted cost (purchasing power parity adjusted) for all member states. Lowest scorers are
highlighted in green, highest in red, and South Africa in yellow for reference. Namibia and Eritrea are considered outliers in the Disease Burden
and DALY weighted cost graphs, respectively, and so the second highest countries are also included
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used to calculate potential improvements from effi-
ciency. The ratio between South Africa and Namibia’s
Int.$ values was 0.035, which suggested all but 3.5%
of the current burden of TB could be averted with
improvements in efficiency.
The cost-efficiency data from the DCPP assumed a
baseline efficacy using the treatment active non-infectious
intervention of 33% for sub-Saharan Africa, with a best
estimate of 71% efficacy. Adopting the treatment latent
infection intervention, which is currently not used in sub-
Saharan Africa and hence has a baseline efficacy of 0%,
would result in a best estimate of 80% efficacy. This means
that efficacy could be improved by 2.42-fold (80/33) using
existing but non-cost-effective interventions.
Using these two ratios (the Int.$ CPP ratio and the
DCPP ratio), the existing DALYs from TB were subdi-
vided as illustrated in Fig. 6. If improvements in effi-
ciency were first adopted, then 972,757.1 (96.5%) DALYs
could have been averted. The resulting 37,080.24 (3.5%)
DALYs could thus be reduced by 2.42-fold with adoption
of non-cost-effective interventions to leave a remainder
of 15,322.41 DALYs (Fig. 6). Alternatively, if existing
non-cost-effective interventions were first adopted, then
592,549.59 (58.68%) DALYs could be averted. Of the
remaining 417,288.45 DALYs, 96.33% could be averted
with gains in efficiency, again leaving a remainder of
15,322.41 DALYs.
Limitations
Of the 15,322.41 DALYs remaining (1.52% of the ori-
ginal DALYs for South Africa), 86.6 are accounted for
by the unavertable with existing interventions estimate.
The remaining 15,235.81 DALYs (1.51% of total DALYs
for South Africa) represent the uncertainty in the
model, as under ideal conditions all DALYs should be
accounted for by the four subsections of the model. It
is unclear what this error is attributable to; however,
the validity of the model can be confirmed by compar-
ing it to the results of other studies. According to the
DCPP, 71% of TB disease burden should currently be
averted in South Africa, yet the amended model figures
show 89.97% (or 94.5% if Namibia is included) is
already being averted. This discrepancy suggests a 1.27-
fold difference between the amended models calcula-
tions and the DCPP calculations. It is not immediately
clear which figure is more accurate, as the DCPP has
limitations such as being modelled on Kenya and using
deaths as opposed to DALYs to quantify efficacy. How-
ever, if the efficacy of the DCPP data was increased
1.27-fold, it would cover the majority of the un-
accounted for DALYs. There is also a degree of uncer-
tainty from the WHO sources of data used in the
model proposed in this paper, as much of the country-
specific data is based on estimates and crude modelling,
and the financial data is supplied by the member states
and not objectively verified. Finally, there is also a
chronological discrepancy between these two data
sources, as previously mentioned.
There are also some limitations with the assumptions
of the model. The simplified addition of prevalence and
incidence to get an estimate of disease burden is crude
and requires more refinement. The model can be recal-
culated on the assumption that either prevalent cases or
incident cases are the only contributors to DALY esti-
mates (Additional file 2). However, the WHO uses both
prevalence and incidence figures in construction of its
DALYs [8], and so it is inaccurate to attribute the total
DALYs to one disease burden measure. The WHO uses
a Generic Disease Modelling System algorithm to com-
pute prevalence and incidence contributions to DALY
estimates, and this algorithm could also potentially be
used to construct disease burden estimates. In terms of
the accuracy of the DALY pp figures, untreated TB can
have a ten year case fatality rate of 70%. Furthermore,
those who survive can still be disabled by TB for as long
as 10 years and TB is mostly a disease of young to
middle-aged adults [20]. As such, the worst case DALY
pp estimate of 13.47 DALYs is definitely within the range
of what could be expected from TB. In terms of that
which is unavertable, a 2006 Tanzanian study suggested
that up to 93% of all disease burden was avertable with
existing interventions [21]. The results herein suggest
Fig. 5 Amended model of TB DALYs for South Africa. South Africa
has an average DALY per person (pp) score of 1.48 and absolute
disease burden of 682,322. Therefore, 0.12 DALYs pp and a disease
burden of 722 are unavertable with existing interventions, but are
too small to see at this scale. South Africa is currently averting a
DALY pp figure of 13.47 and an absolute disease burden of between
747,595 and 1,354,915
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that 98.5% of the TB burden is avertable with existing in-
terventions, which is a reasonable agreement with the
Tanzanian figure.
The amended model also assumes no relatedness be-
tween disease burden and disease severity, and hence
chooses the best and worst DALYs pp and disease bur-
dens independently of each other. In reality, it may be
impossible to impact the disease burden without
impacting the DALYs pp. For example, it is known that
TB interventions have different efficacies depending on
whether the disease is endemic or rare [10], and hence
it may be impossible to achieve both the lowest DALYs
pp and the lowest disease burden simultaneously, as
the model assumes. The assumptions that disease bur-
den and DALY data can be generalised from one coun-
try to another also brings in uncertainty, as there is a
high likelihood of confounding variables playing a role.
However, the identification and elucidation of these
confounders, which lead to such low DALY pp or dis-
ease burden scores, are themselves health systems
questions worthy of research.
This model also does not fully account for the host of
potential confounding variables, such as economies of
scope (health systems gains may benefit multiple disease
outcomes) and climate. While these are acknowledged
as limitations of the model, no attempt is made to con-
trol or adjust the model for them.
Furthermore, even if the model is assumed to be gen-
erally valid, there are still limitations with its applicabil-
ity. Firstly, the amended model only looks at research
area and not at all issues important in priority setting
such as, for example, equity. It is therefore important
that this model be viewed as a component to feed into a
more complex framework, such as the Combined Ap-
proach Matrix model, and not an end to itself. In
addition, while the model suggests the burden of disease
which could be reduced by research area, it does not
quantify how much should be spent on each of those re-
search areas, as different research incurs different costs
and has varying levels of cost-effectiveness [22]. If this
data were available, then the areas of the model could be
weighted as such to reflect cost-effectiveness. However,
given that basic research is typically more expensive than
health systems research, it would most likely exaggerate
the results of the amended model. Thus, research into
the cost-effectiveness of research is required, although
this is a requirement for all priority setting processes,
and not just this specific model. Finally, defining what
area research falls into is sometimes ambiguous. For ex-
ample, a TB vaccine could both reduce the unavertable
component of the disease, be cheaper than current
interventions and be more effectively delivered to the
population. As such, a separate ranking method is re-
quired when evaluating research proposals on a case
by case basis to determine what impact the research
is likely to have. Once the various research proposals
have been defined, the amended model nonetheless
highlights how much of each research area should be
invested in. For example, the importance of health
systems research investments is clearly highlighted in
TB, traditionally a neglected area in research [23],
and suggests that any TB research should have health
systems at the forefront, even if it is a cross-
disciplinary endeavour.
Fig. 6 Subdivision of existing DALYs due to TB for South Africa. In the first graph, reductions from improved efficiency are calculated first,
followed by reductions through use of existing but non-cost-effective interventions. In the second graph, these reductions are applied first,
followed by the reductions from improved efficiency
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A final limitation to the model is the potential for a
disease-specific lens being used to define research prior-
ities, as this would exclude pure health systems research.
This could be addressed by summing all the subsections
of the amended WHO model across all diseases analysed
to get a general idea of how much health systems re-
search is required relative to basic research and biomed-
ical research; however, the validity of such a simple
summation is unclear.
Conclusion
This paper provides the first results at attempting to de-
velop a quantitative-only model and methodology for the
ranking of research priorities. At its current stage, it is a
grossly simplified model, but is widely applicable with lim-
ited data inputs. Further refinements are still required –
the inclusion and weighting of relevant confounding vari-
ables such as socioeconomic factors and comorbidities
could help strengthen the specificity of the model – nor
does the model currently take into account the ranking of
other relevant criteria such as equity, which would need
stakeholder input. Nevertheless, policymakers can use this
model in its current form as an efficient way to graphically
illustrate burden of disease data for multiple diseases, as
well as highlight the relative challenges in tackling those
diseases (health systems, basic research, etc.), both within
the disease and between diseases. This is useful in steering
the desired composition of health research as a whole and
health research within a specific disease field.
Additional files
Additional file 1: Country figures (data summary table).
(DOC 351 kb)
Additional file 2: Disease burden estimates. (DOC 41 kb)
Abbreviations
COHRED: Council On Health Research for Development; CPP: Cost per
patient; DALY: Disability Adjusted Life Year; DALY pp: DALYs per person;
DCPP: Disease Control Priorities Project; Int.$: International dollars;
TB: Tuberculosis; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DH conceived of the study, and both DH and SC participated in its design
and conceptualisation. DH developed the model and collected and analysed
the data presented. SC helped to draft the manuscript, and both authors
read and approved the final manuscript.
Acknowledgements
Particular acknowledgement goes to Dr Gabriela Montorzi, from COHRED, for
mentorship in research priorities, and advice with regards to the amendment
of the model and application to TB. Thanks also to Dr Debbie Bradshaw,
from the South African Medical Research Council Burden of Disease Unit, for
her input on burden of disease data and analysis.
Received: 28 September 2015 Accepted: 28 January 2016
References
1. Tomlinson M, Chopra M, Hoosain N, Rudan I. A review of selected research
priority setting processes at national level in low and middle income
countries: towards fair and legitimate priority setting. Health Res Policy Syst.
2011;9:19.
2. Council on Health Research for Development. Health research, essential link
to equity in development. COHRED; 1990. http://www.cohred.org/
downloads/open_archive/ComReports_0.pdf. Accessed 5 Feb 2016.
3. Council on Health Research for Development. Priority setting for research
for health: toward a management process for low and middle income
countries. COHRED; 2010. http://www.cohred.org/downloads/Essay2.pdf.
Accessed 5 Feb 2016.
4. Ghaffar A, Collins T, Matlin SA, Olifson S. The 3D Combined Approach
Matrix: An improved tool for setting priorities in research for health. Geneva:
Global Forum for Health Research; 2009.
5. Okello D, Chongtrakul P. A manual for research priority setting using the
ENHR strategy. COHRED; 2000. http://www.cohred.org/publications/library-
and-archive/a_manual_for_researc_1_0/. Accessed 5 Feb 2016.
6. Rudan I, Kapiriri L, Tomlinson M, Balliet M, Cohen B, Chopra M. Evidence-
based priority setting for health care and research: tools to support policy
in maternal, neonatal, and child health in Africa. PLoS Med. 2010;7:
e1000308.
7. Rudan I. Global health research priorities: mobilizing the developing world.
Public Health. 2012;126:237–40.
8. World Health Organization. Global Burden of Disease: 2004 Update. WHO;
2009. http://www.who.int/healthinfo/global_burden_disease/2004_report_
update/en/. Accessed 5 Feb 2016.
9. World Health Organization. Global Tuberculosis Control 2006: Surveillance,
Planning, Financing. 2008. http://apps.who.int/bookorders/anglais/detart1.
jsp?codlan=1&codcol=15&codcch=3659. Accessed 5 Feb 2016.
10. Dye C, Floyd K. Disease control priorities in developing countries: Chapter
16 Tuberculosis. Disease Control Priorities Project. http://www.who.int/tb/
features_archive/dcp2/en/. Accessed 5 Feb 2016.
11. Weinzirl J. The action of a high dry climate in the cure of tuberculosis.
Public Health Pap Rep. 1907;33(Pt 1):111–22.
12. Al-Zarouni M, Dash N, Al Ali M, Al-Shehhi F, Panigrahi D. Tuberculosis and
MDR-TB in the northern emirates of United Arab Emirates: a 5-year study.
Southeast Asian J Trop Med Public Health. 2010;41:163–8.
13. Dissanayake S, Usmani A, Sheikh FA, Sheek-Hussein M, Ameen AM, Lukic ML.
Mycobacterium tuberculosis in the United Arab Emirates: evidence of local
transmission with unique strains. Trans R Soc Trop Med Hyg. 2001;95:591–4.
14. Aleksic E, Merker M, Cox H, Reiher B, Sekawi Z, Hearps AC, et al. First
molecular epidemiology study of Mycobacterium tuberculosis in Kiribati.
PLoS One. 2013;8:e55423.
15. Global Education Website. http://www.globaleducation.edu.au/. Accessed 5
Feb 2016.
16. Sagwa E, Mantel-Teeuwisse AK, Ruswa N, Musasa JP, Pal S, Dhliwayo P, et al.
The burden of adverse events during treatment of drug-resistant
tuberculosis in Namibia. South Med Rev. 2012;5:6–13.
17. Ricks PM, Mavhunga F, Modi S, Indongo R, Zezai A, Lambert LA, et al.
Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infect
Dis. 2012;12:385.
18. Haas WH, Engelmann G, Amthor B, Shyamba S, Mugala F, Felten M, et al.
Transmission dynamics of tuberculosis in a high-incidence country:
prospective analysis by PCR DNA fingerprinting. J Clin Microbiol. 1999;37:
3975–9.
19. TB CARE 1 Website: Namibia Country Profile. https://www.usaid.gov/results-
and-data. Accessed 5 Feb 2016.
20. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke
NJD. Natural history of tuberculosis: duration and fatality of untreated
pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS
One. 2011;6:e17601.
21. Tanzania Ministry of Health and Social Welfare. District Health Profile: A
Chart Book of Selected Health and Demographic Indicators. 2007. http://idl-
bnc.idrc.ca/dspace/handle/10625/40905. Accessed 5 Feb 2016.
22. Miller DC, Salkind NJ. Handbook of Research Design & Social Measurement.
6th ed. Thousand Oaks: SAGE Publications; 2002.
23. Ranson MK, Bennett SC. Priority setting and health policy and systems
research. Health Res Policy Syst. 2009;7:27.
Hacking and Cleary Health Research Policy and Systems  (2016) 14:10 Page 11 of 11
